First author 乳癌関連英語論文

  1. Differences in immune response to anesthetics used for day surgery versus hospitalization surgery for breast cancer patients. Clin Transl Med, 2017 (in press).
  2. Outcomes of outpatient breast cancer surgery at a private breast clinic. Breast J, 2017 (in press).
  3. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev 36:159-77, 2017.
  4. Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1-14, 2007.
  5. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 121:149-57, 2007.
  6. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 14:1-11, 2007.
  7. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 7:1006-16, 2006.
  8. The role of apoptosis in cancer cell survival and therapeutic outcome. Cancer Biol Ther 5:1429-42, 2006.
  9. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 146:189-96, 2006.
  10. Cancer immunosuppression and autoimmune disease: Beyond immunosuppressive networks for tumor immunity. Immunology 119:254-64, 2006.
  11. Extranuclear expression of hormone receptors in primary breast cancer. Ann Oncol 17:1213-20, 2006.
  12. Tumor-driven evolution of immunosuppressive network during malignant progression. Cancer Res 66:5527-36, 2006.
  13. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol 32:269-77, 2006.
  14. Role of the unfolded protein response in cell death. Apoptosis 11:5-13, 2006.
  15. Regulation and interplay of apoptotic and nonapoptotic cell death. J Pathol 208:319-26, 2006.
  16. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses. Cancer Biol Ther 4:924-33, 2005.
  17. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 21:1-9, 2005.
  18. Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Bresat Cancer 6: 223-32, 2005.
  19. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 333:336-43, 2005.
  20. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 103:2199-207, 2005.
  21. Recent Advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103:1551-60, 2005.
  22. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101:2491-502, 2004.
  23. The role of FasL and TGF-β in tumor progression; Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100:2281-91, 2004.
  24. Current status of the molecular mechanisms of anticancer drug-induced apoptosis -The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50:343-52, 2002.
  25. Utility of techinetium-99m methoxyisobutylisonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer. Breast Cancer 9:240-7, 2002.
  26. An analysis of relapsed breast cancer in patients previously treated with breast conserving surgery. Breast Cancer 8:146-52, 2001.